Which disease does Cilostazol have an off-label use for?

Cilostazol, a phosphodiesterase type 3 inhibitor, is primarily used for the treatment of intermittent claudication associated with peripheral artery disease. However, it does have an off-label use for Buerger disease (thromboangiitis obliterans), which is a condition characterized by the inflammation and occlusion of blood vessels in the extremities, leading to pain, ulcers, and even gangrene.

The mechanism by which cilostazol helps in Buerger disease involves its ability to inhibit platelet aggregation and promote vasodilation, ultimately enhancing blood flow to the affected regions. As Buerger disease severely affects circulation, cilostazol may help alleviate symptoms by improving blood flow and reducing the frequency of ischemic episodes.

Other conditions listed, such as Raynaud's Disease, Peripheral Artery Disease, and Deep Vein Thrombosis, either do not have a specific off-label indication for cilostazol or are primarily treated with other agents tailored to their pathophysiology.